AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29231146 — intervention group
Group type: EXPERIMENTAL
Intervention: Tintinalli regimen (naloxone 0.1 mg every 2-3 minutes)
Number of subjects: 100
Study 29231146 — intervention group
Group type: COMPARATOR
Intervention: Goldfrank regimen (naloxone starting at 0.04 mg, increasing to 0.4, 2, and 10 mg every 2-3 minutes)
Number of subjects: 100
Study 25796267 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramipril 10 mg daily
Number of subjects: 100
Study 25796267 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 23174253 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoendoscopic single site varicocele ligation with preservation of the testicular artery and lymphatics (Group 1)
Number of subjects: 80
Study 23174253 — intervention group
Group type: COMPARATOR
Intervention: Complete ligation of the testicular vessels and lymphatics (Group 2)
Number of subjects: 80
Study 23174253 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with subfertility in Group 1
Number of subjects: 80
Study 23174253 — intervention group
Group type: COMPARATOR
Intervention: Patients with subfertility in Group 2
Number of subjects: 80
Study 23174253 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with scrotal pain in Group 1
Number of subjects: 80
Study 23174253 — intervention group
Group type: COMPARATOR
Intervention: Patients with scrotal pain in Group 2
Number of subjects: 80
Study 20346089 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine (5 mg for 14 days)
Number of subjects: 25
Study 20346089 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril (10 mg for 14 days)
Number of subjects: 25
Study 20346089 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment (Amlodipine followed by Lisinopril)
Number of subjects: 25
Study 20346089 — intervention group
Group type: COMPARATOR
Intervention: Baseline measurements
Number of subjects: 25
Study 19423854 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluid management guided by daily measurements of blood volume (BV)
Number of subjects: 102
Study 19423854 — intervention group
Group type: COMPARATOR
Intervention: Conventional fluid balance guided fluid therapy
Number of subjects: 102
Study 16442481 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine (2.5 mg every 4 hours) with midazolam rescue doses (5 mg) for breakthrough dyspnea (Group Mo)
Number of subjects: 101
Study 16442481 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam (5 mg every 4 hours) with morphine rescue doses (2.5 mg) for breakthrough dyspnea (Group Mi)
Number of subjects: 101
Study 16442481 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine (2.5 mg every 4 hours) plus midazolam (5 mg every 4 hours) with morphine rescue doses (2.5 mg) for breakthrough dyspnea (Group MM)
Number of subjects: 101
Study 16442481 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly defined, but implied as standard morphine treatment without midazolam)
Number of subjects: 101
Study 14703543 — intervention group
Group type: EXPERIMENTAL
Intervention: Volunteer support from counsellors for breast feeding
Number of subjects: 720
Study 14703543 — intervention group
Group type: COMPARATOR
Intervention: Control group (no volunteer support)
Number of subjects: 720
Study 11359587 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol/remifentanil (PR)
Number of subjects: 80
Study 11359587 — intervention group
Group type: COMPARATOR
Intervention: Propofol (P)
Number of subjects: 80
Study 9256868 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical therapy for 1 month
Number of subjects: 66
Study 9256868 — intervention group
Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 66
Study 8269574 — intervention group
Group type: EXPERIMENTAL
Intervention: Fresh gas flow rates of 5.7 L.min‐1
Number of subjects: 37
Study 8269574 — intervention group
Group type: EXPERIMENTAL
Intervention: Fresh gas flow rates of 8.0 L.min‐1
Number of subjects: 37
Study 8269574 — intervention group
Group type: EXPERIMENTAL
Intervention: Fresh gas flow rates of 9.3 L.min‐1
Number of subjects: 37
Study 8269574 — intervention group
Group type: EXPERIMENTAL
Intervention: Fresh gas flow rates of 10.4 L.min‐1
Number of subjects: 37
Study 3739696 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenylpropanolamine (Ppa)
Number of subjects: 17
Study 3739696 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical exercise
Number of subjects: 17
Study 3739696 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 29435828 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination or bridging therapy (C/BT)
Number of subjects: 188
Study 26538582 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking pace >3 mph
Number of subjects: 4207
Study 26538582 — intervention group
Group type: COMPARATOR
Intervention: Walking pace <2 mph
Number of subjects: 4207
Study 25816544 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterior pericardiotomy (PP)
Number of subjects: 20
Study 25816544 — intervention group
Group type: COMPARATOR
Intervention: Control (no posterior pericardiotomy)
Number of subjects: 20
Study 22817833 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 mg ranibizumab
Number of subjects: 789
Study 22817833 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg ranibizumab
Number of subjects: 789
Study 22817833 — intervention group
Group type: COMPARATOR
Intervention: Sham
Number of subjects: 789
Study 21189203 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion of bupivacaine via a popliteal catheter for 72 hours
Number of subjects: 54
Study 21189203 — intervention group
Group type: COMPARATOR
Intervention: Normal saline via a popliteal catheter for 72 hours (Control)
Number of subjects: 54
Study 18179318 — intervention group
Group type: EXPERIMENTAL
Intervention: Internal motivation for nonprejudiced responses
Number of subjects: 0
Study 18179318 — intervention group
Group type: COMPARATOR
Intervention: Combination of internal and external motivation for nonprejudiced responses
Number of subjects: 0
Study 18179318 — intervention group
Group type: EXPERIMENTAL
Intervention: Conflict monitoring activity measured by event-related potentials
Number of subjects: 0
Study 18179318 — intervention group
Group type: EXPERIMENTAL
Intervention: Response control in the domain of prejudice
Number of subjects: 0
Study 15712768 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic touch
Number of subjects: 57
Study 15712768 — intervention group
Group type: COMPARATOR
Intervention: Placebo therapeutic touch
Number of subjects: 57
Study 15712768 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 57
Study 12670812 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal + PCA morphine (IT+PCA)
Number of subjects: 60
Study 12670812 — intervention group
Group type: COMPARATOR
Intervention: PCA morphine alone
Number of subjects: 60
Study 12670812 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 60
Study 10767356 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral doxifluridine (group A)
Number of subjects: 150
Study 10767356 — intervention group
Group type: COMPARATOR
Intervention: 5-fluorouracil (group B)
Number of subjects: 150
Study 9310220 — intervention group
Group type: EXPERIMENTAL
Intervention: r-hIFN-beta-1a (1 million IU, intralesional, 3 times a week for 9 occasions)
Number of subjects: 60
Study 9310220 — intervention group
Group type: COMPARATOR
Intervention: Placebo (intralesional, 3 times a week for 9 occasions)
Number of subjects: 60
Study 9310220 — intervention group
Group type: EXPERIMENTAL
Intervention: r-hIFN-beta-1a
Number of subjects: 60
Study 8422744 — intervention group
Group type: EXPERIMENTAL
Intervention: Levonorgestrel (250 mg) and Ethinyl Estradiol (50 micrograms)
Number of subjects: 1055
Study 8422744 — intervention group
Group type: COMPARATOR
Intervention: Desogestrel (150 micrograms) and Ethinyl Estradiol (30 micrograms)
Number of subjects: 1055
Study 8422744 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 1055
Study 2947150 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimetazidine (20 mg per tablet, 3 tablets daily for one month)
Number of subjects: 32
Study 2947150 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 31399480 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed-loop insulin delivery
Number of subjects: 2
Study 31399480 — intervention group
Group type: COMPARATOR
Intervention: Paper guidance
Number of subjects: 2
Study 29459121 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise and manual therapy
Number of subjects: 45
Study 29459121 — intervention group
Group type: COMPARATOR
Intervention: Exercise and manual therapy + IFC
Number of subjects: 45
Study 29459121 — intervention group
Group type: COMPARATOR
Intervention: Exercise and manual therapy + placebo ultrasound
Number of subjects: 45
Study 26884473 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-acting (pegylated) C-peptide 0.8 mg
Number of subjects: 250
Study 26884473 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-acting (pegylated) C-peptide 2.4 mg
Number of subjects: 250
Study 26884473 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined C-peptide groups
Number of subjects: 250
Study 26884473 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 250
Study 26884473 — intervention group
Group type: EXPERIMENTAL
Intervention: C-peptide therapy
Number of subjects: 250
Study 24753534 — intervention group
Group type: EXPERIMENTAL
Intervention: ≥2 anxiety comorbidities (n = 143; 39%)
Number of subjects: 392
Study 24753534 — intervention group
Group type: COMPARATOR
Intervention: No anxiety comorbidities (n = 132; 36%)
Number of subjects: 392
Study 24753534 — intervention group
Group type: COMPARATOR
Intervention: 1 anxiety comorbidity (n = 95; 26%)
Number of subjects: 392
Study 23718253 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamins C and E
Number of subjects: 685
Study 23718253 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 685
Study 20347616 — intervention group
Group type: COMPARATOR
Intervention: Placebo-controlled trials
Number of subjects: 0
Study 18391603 — intervention group
Group type: EXPERIMENTAL
Intervention: LMI alone
Number of subjects: 61
Study 18391603 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide followed by LMI
Number of subjects: 61
Study 18391603 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide followed by LMI with IL-2
Number of subjects: 61
Study 16466758 — intervention group
Group type: EXPERIMENTAL
Intervention: Equine F(ab')2 antivenom
Number of subjects: 28
Study 16466758 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 14725391 — intervention group
Group type: EXPERIMENTAL
Intervention: Life review and reminiscence therapies
Number of subjects: 0
Study 14725391 — intervention group
Group type: COMPARATOR
Intervention: Traditional forms of counselling and psychotherapy
Number of subjects: 0
Study 10944641 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron 1 microg/kg twice per day
Number of subjects: 321
Study 10944641 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron 4 microg/kg twice per day
Number of subjects: 321
Study 10944641 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron 16 microg/kg twice per day
Number of subjects: 321
Study 10944641 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 321
Study 8998919 — intervention group
Group type: EXPERIMENTAL
Intervention: 23-valent vaccine of capsular polysaccharides (Pneumovax 23)
Number of subjects: 31
Study 8998919 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (23 subjects)
Number of subjects: 31
Study 8998919 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart transplantation
Number of subjects: 31
Study 8998919 — intervention group
Group type: EXPERIMENTAL
Intervention: Liver transplantation
Number of subjects: 31
Study 30376884 — intervention group
Group type: EXPERIMENTAL
Intervention: Eplerenone 25 mg every 12 hours for 4 days (first dose prior to kidney transplantation)
Number of subjects: 132
Study 30376884 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 132
Study 30376884 — intervention group
Group type: EXPERIMENTAL
Intervention: Eplerenone
Number of subjects: 132
Study 27070853 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Intervention for Social Anxiety Disorder (MBI-SAD)
Number of subjects: 21
Study 27070853 — intervention group
Group type: COMPARATOR
Intervention: Waitlist Control (WL)
Number of subjects: 21
Study 26576424 — intervention group
Group type: COMPARATOR
Intervention: Propofol (1.5 mg/kg)
Number of subjects: 90
Study 26576424 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (1.5 mg/kg) + Remifentanil (0.05 μg/kg)
Number of subjects: 90
Study 26576424 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (1.5 mg/kg) + Fentanyl (1 μg/kg)
Number of subjects: 90
Study 23995984 — intervention group
Group type: EXPERIMENTAL
Intervention: Restrictive RBC transfusion strategy (Hb 8.0 g/dl)
Number of subjects: 107
Study 23995984 — intervention group
Group type: COMPARATOR
Intervention: Liberal RBC transfusion strategy (Hb 10.8 g/dl)
Number of subjects: 107
Study 23995984 — intervention group
Group type: EXPERIMENTAL
Intervention: Restrictive RBC transfusion strategy
Number of subjects: 107
Study 23995984 — intervention group
Group type: COMPARATOR
Intervention: Liberal RBC transfusion strategy
Number of subjects: 107
Study 20655177 — intervention group
Group type: EXPERIMENTAL
Intervention: Dento‐alveolar distraction
Number of subjects: 6
Study 20655177 — intervention group
Group type: COMPARATOR
Intervention: Periodontal distraction
Number of subjects: 6
Study 18830037 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate
Number of subjects: 0
Study 16439935 — intervention group
Group type: EXPERIMENTAL
Intervention: Dérinox (D)
Number of subjects: 354
Study 16439935 — intervention group
Group type: COMPARATOR
Intervention: Rhinofluimucil (R)
Number of subjects: 354
Study 16439935 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 354
Study 11875365 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolbutamide (500 mg)
Number of subjects: 18
Study 11875365 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 10359022 — intervention group
Group type: EXPERIMENTAL
Intervention: LCP1 formula (0.31% 18:3 omega6, 0.17% 20:5 omega3, 0.20% 22:6 omega3)
Number of subjects: 47
Study 10359022 — intervention group
Group type: EXPERIMENTAL
Intervention: LCP2 formula (0.32% 18:3 omega6, 0.34% 20:5 omega3, 0.43% 22:6 omega3)
Number of subjects: 47
Study 10359022 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary 20:5 omega3 and 22:6 omega3
Number of subjects: 47
Study 10359022 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary 20:5 omega3 and LCPUFA omega3
Number of subjects: 47
Study 10359022 — intervention group
Group type: EXPERIMENTAL
Intervention: LCP1 and LCP2 fed infants
Number of subjects: 47
Study 10359022 — intervention group
Group type: EXPERIMENTAL
Intervention: Added 18:3 omega6
Number of subjects: 47
Study 10359022 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil
Number of subjects: 47
Study 7735582 — intervention group
Group type: EXPERIMENTAL
Intervention: Modipafant (50 mg capsule twice daily)
Number of subjects: 120
Study 7735582 — intervention group
Group type: COMPARATOR
Intervention: Placebo (matched placebo)
Number of subjects: 120
Study 1688330 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxatomide gel 5% (2 applications a day for 7 days)
Number of subjects: 20
Study 1688330 — intervention group
Group type: COMPARATOR
Intervention: Placebo (2 applications a day for 7 days)
Number of subjects: 20
Study 6794584 — intervention group
Group type: EXPERIMENTAL
Intervention: Lysine acetyl salicylate (LAS) 1.8 g
Number of subjects: 0
Study 6794584 — intervention group
Group type: COMPARATOR
Intervention: Morphine 10 mg
Number of subjects: 0
Study 30646890 — intervention group
Group type: EXPERIMENTAL
Intervention: Dental caries experience
Number of subjects: 90
Study 28141630 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Electroconvulsive Therapy (MECT)
Number of subjects: 100
Study 28141630 — intervention group
Group type: COMPARATOR
Intervention: Atypical antipsychotic treatment
Number of subjects: 100
Study 28141630 — intervention group
Group type: COMPARATOR
Intervention: Control (Healthy controls)
Number of subjects: 100
Study 26510464 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (iNO) at 80 ppm by non-rebreather mask
Number of subjects: 180
Study 26510464 — intervention group
Group type: COMPARATOR
Intervention: Placebo (room air)
Number of subjects: 180
Study 23340761 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic technique
Number of subjects: 90
Study 23340761 — intervention group
Group type: COMPARATOR
Intervention: Classic incision
Number of subjects: 90
Study 23340761 — intervention group
Group type: COMPARATOR
Intervention: Short incision
Number of subjects: 90
Study 19950112 — intervention group
Group type: EXPERIMENTAL
Intervention: Body checking
Number of subjects: 66
Study 19950112 — intervention group
Group type: COMPARATOR
Intervention: Body exposure
Number of subjects: 66
Study 19950112 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 66
Study 19254629 — intervention group
Group type: EXPERIMENTAL
Intervention: Implantable cardioverter defibrillators (ICDs)
Number of subjects: 57
Study 17397061 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment (10-week functional continuous magnetic stimulation)
Number of subjects: 39
Study 17397061 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment (initial 10-week sham treatment)
Number of subjects: 39
Study 15061748 — intervention group
Group type: COMPARATOR
Intervention: Vitamin E supplementation
Number of subjects: 84
Study 11282809 — intervention group
Group type: EXPERIMENTAL
Intervention: Bright white light
Number of subjects: 57
Study 11282809 — intervention group
Group type: COMPARATOR
Intervention: Dim red light
Number of subjects: 57
Study 19160722 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol 100 mg o.d.
Number of subjects: 52
Study 19160722 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine 5 mg o.d.
Number of subjects: 52
Study 19160722 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 8387912 — intervention group
Group type: EXPERIMENTAL
Intervention: Isabgol husk (25 g) added to low-fibre diet
Number of subjects: 11
Study 8387912 — intervention group
Group type: COMPARATOR
Intervention: Low-fibre diet (control)
Number of subjects: 11
Study 3111669 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg sodium fluoride (NaF) + 1 g calcium
Number of subjects: 25
Study 3111669 — intervention group
Group type: COMPARATOR
Intervention: 10 mg sodium fluoride (NaF) + calcium
Number of subjects: 25
Study 3111669 — intervention group
Group type: COMPARATOR
Intervention: Calcium alone
Number of subjects: 25
Study 3111669 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 26305570 — intervention group
Group type: EXPERIMENTAL
Intervention: Transfusion (Tx)
Number of subjects: 80
Study 26305570 — intervention group
Group type: COMPARATOR
Intervention: Standard Care (SC)
Number of subjects: 80
Study 24281460 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivitamins plus selenium
Number of subjects: 878
Study 24281460 — intervention group
Group type: COMPARATOR
Intervention: Multivitamins alone
Number of subjects: 878
Study 24281460 — intervention group
Group type: COMPARATOR
Intervention: Selenium alone
Number of subjects: 878
Study 24281460 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 878
Study 21054362 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolmitriptan 5 mg
Number of subjects: 1315
Study 21054362 — intervention group
Group type: EXPERIMENTAL
Intervention: Telcagepant 150 mg
Number of subjects: 1315
Study 21054362 — intervention group
Group type: EXPERIMENTAL
Intervention: Telcagepant 300 mg
Number of subjects: 1315
Study 21054362 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1315
Study 18494811 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice-daily 50/50 premixed insulin lispro (Mix50 group)
Number of subjects: 28
Study 18494811 — intervention group
Group type: COMPARATOR
Intervention: Basal-bolus (BB) therapy (NPH insulin at bedtime and preprandial insulin lispro)
Number of subjects: 28
Study 16541853 — intervention group
Group type: EXPERIMENTAL
Intervention: Reducing south and reinforcing north needling method
Number of subjects: 90
Study 16541853 — intervention group
Group type: COMPARATOR
Intervention: Capoten and aspirin
Number of subjects: 90
Study 12437644 — intervention group
Group type: EXPERIMENTAL
Intervention: High sCD62L levels
Number of subjects: 193
Study 12437644 — intervention group
Group type: EXPERIMENTAL
Intervention: Low sCD62L levels
Number of subjects: 193
Study 12437644 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal sCD62L levels
Number of subjects: 193
Study 12437644 — intervention group
Group type: EXPERIMENTAL
Intervention: Low, normal, and high sCD62L levels in non-S3/S4 patients
Number of subjects: 193
Study 10326217 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly L-asparaginase (l-Asp) during maintenance therapy as a late intensification
Number of subjects: 62
Study 10326217 — intervention group
Group type: COMPARATOR
Intervention: Standard maintenance therapy without additional L-asparaginase (l-Asp)
Number of subjects: 62
Study 10326217 — intervention group
Group type: EXPERIMENTAL
Intervention: Full dose of daunorubicin (DNR, 450 mg/m2 in total)
Number of subjects: 62
Study 10326217 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall treatment protocol AL841
Number of subjects: 62
Study 10326217 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete remission (CR) achieved with three-drug induction
Number of subjects: 62
Study 7472590 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetrofosmin
Number of subjects: 30
Study 7472590 — intervention group
Group type: COMPARATOR
Intervention: Sestamibi
Number of subjects: 30
Study 1937073 — intervention group
Group type: EXPERIMENTAL
Intervention: Argon-laser trabeculoplasty (performed on one eye)
Number of subjects: 25
Study 1937073 — intervention group
Group type: COMPARATOR
Intervention: Control (fellow eye, no treatment)
Number of subjects: 25
Study 6811177 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil 360 mg daily
Number of subjects: 28
Study 6811177 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 31124409 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug treatment involving COMT modulation
Number of subjects: 0
Study 31124409 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 0